SALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, 28040 Madrid, Spain.
Vaccine. 2011 Oct 13;29(44):7867-74. doi: 10.1016/j.vaccine.2011.07.091. Epub 2011 Aug 2.
At present, there is no effective treatment or vaccine to prevent vertical transmission or abortion associated with Neospora caninum infection in cattle. Different vaccine formulations have been assayed, and live vaccines have shown the most promising results in terms of protection. Previously, transgenic N. caninum tachyzoites expressing the bradyzoite stage-specific NcSAG4 antigen in a constitutive manner (Nc-1 SAG4(c)) were obtained and showed a reduced persistence of parasite in inoculated mice. Thus, the present study evaluates the Nc-1 SAG4(c)1.1 and Nc-1 SAG4(c)2.1 transgenic strains and the Nc-1 wild-type (WT) strain to determine their protective efficacy against vertical transmission and cerebral neosporosis in mice. Consequently, dams were immunized twice with 5 × 10(5) tachyzoites of each strain and challenged with 2 × 10(6) tachyzoites of a heterologous and virulent isolate at 7-10 days of gestation. The Nc-1 SAG4(c)1.1 strain offered less protection than the other transgenic strain (Nc-1 SAG4(c)2.1) or their ancestor (Nc-1 WT). Indeed, 40%, 7% and 5.6% of the postnatal deaths corresponded to pups from dams vaccinated with Nc-1 SAG4(c)1.1, Nc-1 SAG4(c)2.1 and Nc-1 (WT) strains, respectively. In comparison, the non-immunized challenge group had a 100% mortality rate. In addition, mice were protected against congenital transmission; vertical transmission rates were 45%, 11.1% and 10.8% in the Nc-1 SAG4(c)1.1, Nc-1 SAG4(c)2.1 and Nc-1 WT immunized groups, respectively, vs. 94.9% in the non-vaccinated infected group. However, this protection against the postnatal mortality and the vertical transmission was not associated with a consistent Th1 or Th2-type immune response. Nonetheless, the Nc-1 SAG4(c)2.1 strain appears to be the best candidate for use as a live vaccine, as evidenced by results demonstrating its high levels of protection against vertical transmission and its lower persistence in mice, making this transgenic strain safer than Nc-1 WT.
目前,尚无有效的治疗方法或疫苗可预防与刚地弓形虫感染相关的牛垂直传播或流产。已经对不同的疫苗制剂进行了评估,活疫苗在保护方面显示出最有前途的结果。以前,通过在组成型方式下表达缓殖子期特异性 NcSAG4 抗原的转基因刚地弓形虫速殖子(Nc-1 SAG4(c))已被获得,并显示出在接种小鼠中寄生虫持续存在减少。因此,本研究评估了 Nc-1 SAG4(c)1.1 和 Nc-1 SAG4(c)2.1 转基因株系以及 Nc-1 野生型(WT)株系,以确定它们对垂直传播和小鼠脑部新孢子虫病的保护效力。结果,母鼠用 5×10(5)个各株系的速殖子进行两次免疫,并在妊娠 7-10 天用 2×10(6)个异源和毒力分离株的速殖子进行攻毒。Nc-1 SAG4(c)1.1 株系的保护作用不如其他转基因株系(Nc-1 SAG4(c)2.1)或其祖先(Nc-1 WT)。实际上,来自用 Nc-1 SAG4(c)1.1、Nc-1 SAG4(c)2.1 和 Nc-1(WT)株系免疫的母鼠的新生后死亡的幼仔分别为 40%、7%和 5.6%。相比之下,未免疫的攻毒组死亡率为 100%。此外,小鼠还受到先天性传播的保护;Nc-1 SAG4(c)1.1、Nc-1 SAG4(c)2.1 和 Nc-1 WT 免疫组的垂直传播率分别为 45%、11.1%和 10.8%,而非未接种感染组为 94.9%。然而,这种对新生后死亡率和垂直传播的保护作用与一致的 Th1 或 Th2 型免疫反应无关。尽管如此,Nc-1 SAG4(c)2.1 株系似乎是作为活疫苗使用的最佳候选者,这从其对垂直传播的高保护水平和在小鼠中的低持续存在证明了这一点,使其比 Nc-1 WT 更安全。